Fig. 1: Areas for improving the definition of metabolic and alcohol-related liver disease (MetALD) for clinical trials.
DECEMBER ISSUE | REVIEW "Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease"
www.nature.com/articles/s41...
#Liversky
🆕CPG in press❕
EASL Clinical Practice Guidelines on vascular diseases of the liver
Find it here👉www.journal-of-hepatology.eu/article/S0168-8278(25)02...
#LiverSky
@easlnews.bsky.social
🚨Not every elevation of Creatinine in a corrhotic patient is #HRS!
When faced with AKI in cirrhosis, assess your patient as a whole. This ABCD framework is very helpful
And here are the updated definitions as well!
#TLM25 #LiverSky @aasldnews.bsky.social
UC Riverside identified a PTPN2 gene mutation in up to 20% of #IBD patients that disrupts iron absorption, explaining persistent #anemia despite oral supplements. This insight could shift treatment toward IV iron for better outcomes and highlights genetics’ role in IBD complications.
In the #RedJournal:
Granulocyte Colony-Stimulating Factor Improves Prednisolone Responsiveness and 90-Day Survival in Steroid-Eligible Severe Alcohol-Associated Hepatitis: The GPreAH Study a Randomized Trial
Mishra & Shasthry, et al.
📕 bit.ly/43onq7X
🎓 Jean-Pierre Benhamou Clinical State-of-the-Art
🗣️ @docberza.bsky.social on The promise & pitfalls of non-invasive testing – #EASL2025
🧪 NITs: from fibrosis staging ➡️ to prognosis
📈 Last LSM value matters
🔬 OMICS + evolving algorithms = the future
⏳ Baveno VIII will guide next steps
Do we need to treat cirrhotic PVT, and how? – #EASL2025
🗣️ @jcgarciapagan
📍 LT candidate → anticoagulate if >25%
🚫 No LT → consider if >50%
🔍 Anticoagulation may help beyond recanalization
🛠️ Radiological Rx: for LT candidates not responding or with refractory CSPH
🩸 Haemostatic management during procedures in cirrhosis
🗣️ N. Intagliata – #EASL2025
✅ Bleeding is rare, but serious
🚫 Standard tests ≠ bleeding risk
📌 Consider procedure risk, cirrhosis stage & BMI
📋 Have a bleeding plan
🧪 Viscoelastic tests: promising future tool
🩸 Managing acute bleeding in cirrhosis
🗣️ Lara Roberts (London) – #EASL2025
✅ Restrictive transfusion
🚫 No FFP, no tranexamic acid
❓ Platelets & fibrinogen: no clear evidence
🔮 Future: viscoelastic tests to guide therapy?
💊 DOACs in cirrhosis
🗣️ Cindy Pereira Portela (Lausanne) – #EASL2025
✅ Child A/B: ok (⚠️ no rivaroxaban in B)
🚫 Child C: not recommended
⭐ Apixaban might be the winner — but more data needed
🧩 Case-by-case decision
🤝 Multidisciplinary approach is essential
Highlights of @docberza.bsky.social talk on NITs @easlnews.bsky.social #easlcongress
We need to use @bavenocoop.bsky.social
dual stiffness cutoffs more often and u suspect this is the way of the future.
#liversky
mRNA-1083 shows superior immune response against influenza and COVID-19 in adults 50 and older, with acceptable safety.
by Rudman Spergel AK, Wu I (...) Shaw CA et 16 al. in JAMA #MedSky
👉 get more here
📖 read the article:
First first author article for Eemeli Puhakka published!
We identified a profile of metabolites separating those with early stage progressive alcohol-related liver disease from non-progressive alcohol-related liver disease using metabolomics
doi.org/10.1111/liv....
#metabolomics #alcohol
Acute Kidney Injury in Patients with Cirrhosis
"The authors review the pathophysiology, revised diagnostic definitions, and management of acute kidney injury, a common condition in patients with cirrhosis."
www.nejm.org/doi/full/10....
How often do u get asked to “clear” patients w/cirrhosis for surgery?
How about “just” being on board?
#liversky
Well, if u want to get on board, here is your next read 👇🏼
Guidelines on abdominal surgery in patients w/cirrhosis
@jhepatology.bsky.social
www.journal-of-hepatology.eu/article/S016...
What’s new on Hep B treatment guidelines?
#liversky
EASL Clinical Practice Guidelines on the management of hepatitis B virus infection
www.journal-of-hepatology.eu/article/S016...
@jhepatology.bsky.social
Great summary of advances in LRT and systemic treatments for HCC
#liversky
www.gastrojournal.org/article/S001...
@amergastroassn.bsky.social
A practical review of new AGA guidance on PVT management by @drjessicadavis.bsky.social
#liversky
📍don’t delay AC
📍can hold AC for EGD for 48 hours
📍AC does NOT increase risk of bleeding from varices while you wait for EGD
Treating itch in liver disease
A review from 2017 t.co/NTrAg73AP1
What has changed?
New PPARs and IBAT but access will be limited
#liversky
Incidence of cancer in PSC
#liversky
Leveraging old hepatitis C therapies
via @nejm.org
www.nejm.org/doi/full/10....
#LiverSky #HepSky #IDSky
Updated HCC management guidelines by @easlnews.bsky.social
Must read 👇🏼👇🏼👇🏼
www.journal-of-hepatology.eu/article/S016...
#Liversky
Next, Elizabeth Powell charts the momentous changes in #MASLD research and treatment in 2024, from first drug approval to updated guidelines and new biomarkers
www.nature.com/articles/s41...
🔓https://rdcu.be/d0QD8
#LiverSky #Gastrosky
HCC can develop in pts with MASLD, even in the absence of cirrhosis, but current guidelines only recommend screening in MASH cirrhosis ☝🏼🤔
Liver stiffness measurement (LSM) can offer a way to identify those non-cirrhotic pts at high risk of HCC. Dr. Binu John
The Red Journal debuts on #BlueSky
The American Journal of #Gastroenterology
#GastroSky #LiverSky
📕 bit.ly/AmJGastro
Suffering from success
What is the risk of progression to liver disease with high risk alcohol use?
Ponni Perumalswami shares natural history and modifiable risk factors at #TLM2024
